Results 61 to 70 of about 3,046,243 (224)
Oman Medical Journal, 2014 The risk of thrombosis is high in patients with essential thrombocythemia. Special precaution needed for those patients who will undergo Coronary artery bypass grafting. We are reporting a 62 years old patient with ischemic heart disease who was found to
Edem Ziadinov +3 more
doaj +1 more source
American Journal of Hematology, Volume 100, Issue 11, Page 2028-2039, November 2025.ABSTRACT Selecting the optimal donor is crucial for optimizing results of allogeneic hematopoietic cell transplantation (allo‐HCT). We analyzed outcomes based on donor type in 2809 myelofibrosis (MF) patients undergoing first allo‐HCT between 2015 and 2021 at EBMT centers.
Juan Carlos Hernández‐Boluda +24 more
wiley +1 more source
Blood, 2019 Prior studies have reported high response rates with recombinant interferon-α (rIFN-α) therapy in patients with essential thrombocythemia (ET) and polycythemia vera (PV).
A. Yacoub +33 more
semanticscholar +1 more source
The Essential Thrombocythemia, Thrombotic Risk Stratification, and Cardiovascular Risk Factors
Advances in Hematology, 2020 Essential thrombocythemia is a rare hematological malignancy with good overall survival, but moderate to high risk of developing arterial or venous thrombosis lifelong.
S. Mancuso +9 more
semanticscholar +1 more source
American journal of hematology/oncology, 2018 Disease Overview: Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms respectively characterized by erythrocytosis and thrombocytosis; other disease features include leukocytosis, splenomegaly, thrombosis, bleeding,
A. Tefferi, T. Barbui
semanticscholar +1 more source
Hematology Reports, 2022 Essential thrombocythemia, as defined by the WHO in 2016, is a Philadelphia-negative chronic myeloproliferative neoplasm showing a better prognosis than polycythemia vera and myelofibrosis.
Marco Santoro +7 more
doaj +1 more source
Emerging treatments for essential thrombocythemia
Journal of Blood Medicine, 2011 Steven Okoli, Claire HarrisonDepartment of Haematology, Guy's and St Thomas' NHS Foundation Trust, Great Maze Pond, London, UKAbstract: In 1934, Epstein and Goedel used the term hemorrhagic thrombocythemia to describe a disorder ...
Okoli S, Harrison C
doaj
AP2M1 Is a Candidate Gene for Microcephaly and Intellectual Disability in 3q27.1 Deletions
American Journal of Medical Genetics Part A, Volume 197, Issue 11, November 2025.ABSTRACT Deletions of the 3q26.33q27.2 region appear to correlate with a distinct phenotype, although there are few reported cases. Here, we present seven previously unreported individuals carrying de novo 3q27 deletions (under 5 Mb), which include the AP2M1 (adaptor‐related protein complex 2, mu‐1 subunit) gene and summarize data from 12 previously ...
Russell Gear +16 more
wiley +1 more source
Haematologica, 2017 The myeloproliferative neoplasms, including polycythemia vera, essential thrombocythemia and myelofibrosis, are distinguished by their debilitating symptom profiles, life-threatening complications and profound impact on quality of life.
Holly L. Geyer +51 more
doaj +1 more source
A Case of Myeloproliferative Neoplasm‐Associated Glomerulopathy in a Patient With Myelofibrosis
Clinical Case Reports, Volume 13, Issue 11, November 2025.ABSTRACT Myeloproliferative neoplasm (MPN)‐related glomerulopathy is a rare, late complication of MPN. Mesangial matrix expansion seems to be the histopathological hallmark. Proteinuria may not always be present. Further exploration is warranted to determine whether risk factors—including disease entity, mutation status and treatment regimens ...
Saskia Leibowitz +4 more
wiley +1 more source